KAZIMI A J

KAZIMI A J, Chairman and CEO of an undisclosed company, has demonstrated a clear buying bias in their trading activity, with $286,171.60 in total purchases compared to just $17,885.70 in sales across 150 transactions—all involving CPIX (Cumberland Pharmaceuticals). The most recent activity includes a significant $280,000 acquisition of CPIX shares on March 18, 2026, following a smaller sale of $17,885.70 two days prior. Prior to these transactions, KAZIMI engaged in a series of smaller purchases throughout late 2025, with values ranging from $30.24 to $45.78 per transaction between November 28 and December 19, 2025. The pattern suggests a sustained accumulation of CPIX shares, with only sporadic selling. The December 2025 transactions were relatively modest, typically under $50 per trade, while the March 2026 purchase marked a substantial increase in investment. The lack of recent sales aside from the single March 16 transaction reinforces a long-term holding strategy. Given the absence of trades in other securities, KAZIMI’s focus appears concentrated on CPIX, with the bulk of their activity reflecting confidence in the company through repeated acquisitions.